Company Filing History:
4 out of 263 
4 out of 987 
2 out of 167 Years Active: 2018-2023
Title: The Innovative Contributions of Charles Coombes
Introduction
Charles Coombes is a notable inventor based in London, GB. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target cyclin-dependent kinases (CDKs). With a total of 4 patents to his name, Coombes has been instrumental in advancing therapeutic options for various disorders.
Latest Patents
One of Coombes' latest patents involves pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds that act as CDK inhibitors. These compounds are designed to inhibit various CDKs, including CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, and CDK13. The patent outlines pharmaceutical compositions that utilize these compounds to treat disorders associated with CDK activity, such as cancer, viral infections, neurodegenerative disorders, ischaemia, renal diseases, and cardiovascular disorders. The treatment may also include simultaneous or sequential administration of additional active agents, enhancing the therapeutic efficacy.
Career Highlights
Throughout his career, Charles Coombes has worked with prominent organizations, including Cancer Research Technology Limited and Emory University. His work has focused on developing innovative solutions to combat serious health issues, particularly in the realm of cancer research.
Collaborations
Coombes has collaborated with notable colleagues such as Alexander Bondke and Sebastian Kroll. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.
Conclusion
Charles Coombes exemplifies the spirit of innovation in the field of medicinal chemistry. His work on CDK inhibitors has the potential to significantly impact the treatment of various diseases, showcasing the importance of continued research and development in this area.